Sarah Dolman


Sarah is a senior client advisor on science and technology innovations in life sciences and healthcare. She has helped multiple AI-enabled biotech companies focus programs to speed their path to commercialize R&D assets. Previously, Sarah was a member of the Strategy team at Verily Life Sciences, where she helped refine product roadmaps and commercial launch plans for both the clinical study platform, and a novel, stain-free, pathology tool. Sarah’s work in strategy began at the Boston Consulting Group, where she helped biopharma & med-tech clients rebalance R&D programs and improve supply-operations.  Prior to BCG, Sarah was a Director at Merck, where she led teams in Process Research & Chemistry supporting R&D efforts across multiple TAs, including cardiovascular, infectious, and metabolic diseases. 

Sarah has a PhD in Organic Chemistry from MIT, an MBA from NYU-Stern, and a BSc from the University of Toronto.